Skip to main content
PMC home page
CNS Drug Reviews logoLink to CNS Drug Reviews
. 2006 Jun 7;7(4):445–470. doi: 10.1111/j.1527-3458.2001.tb00210.x

Galanin: Neurobiologic Mechanisms and Therapeutic Potential for Alzheimer's Disease

Scott E Counts 1, Sylvia E Perez 1, Ulrika Kahl 2, Tamas Bartfai 2, Robert P Bowser 3, Darlene C Deecher 4, Deborah C Mash 5, Jacqueline N Crawley 6, Elliott J Mufson 1,✉
PMCID: PMC6741671  PMID: 11830760

ABSTRACT

The neuropeptide galanin (GAL) is widely distributed in the mammalian CNS. Several lines of evidence suggest that GAL may play a critical role in cognitive processes such as memory and attention through an inhibitory modulation of cholinergic basal forebrain activity. Furthermore, GAL fibers hyperinnervate remaining cholinergic basal forebrain neurons in Alzheimer's disease (AD). This suggests that GAL activity impacts cholinergic dysfunction in advanced AD. Pharmacological and in vitro autoradiographic studies indicate the presence of heterogeneous populations of GAL receptor (GALR) sites in the basal forebrain which bind GAL with both high and low affinity. Interestingly, we have recently observed that GALR binding sites increase in the anterior basal forebrain in late‐stage AD. Three G protein‐coupled GALRs have been identified to date that signal through a diverse array of effector pathways in vitro, including adenylyl cyclase inhibition and phospholipase C activation. The repertoire and distribution of GALR expression in the basal forebrain remains unknown, as does the nature of GAL and GALR plasticity in the AD basal forebrain. Recently, GAL knockout and overexpressing transgenic mice have been generated to facilitate our understanding of GAL activity in basal forebrain function. GAL knockout mice result in fewer cholinergic basal forebrain neurons and memory deficits. On the other hand, mice overexpressing GAL display hyperinnervation of basal forebrain and memory deficits. These data highlight the need to explore further the putative mechanisms by which GAL signaling might be beneficial or deleterious for cholinergic cell survival and activity within basal forebrain. This information will be critical to understanding whether pharmacological manipulation of GALRs would be effective for the amelioration of cognitive deficits in AD.

Keywords: Alzheimer's disease, Galanin, Galanin receptors

Full Text

The Full Text of this article is available as a PDF (567.0 KB).

References

  • 1. Bartus RT, Dean RL, 3rd , Beer B, Lippa AS. The cholinergic hypothesis of geriatric memory dysfunction. Science 1982;217 (4558): 408–414. [DOI] [PubMed] [Google Scholar]
  • 2. Baxter MG, Chiba AA. Cognitive functions of the basal forebrain. Curr Opin Neurobiol 1999;9 (2): 178–183. [DOI] [PubMed] [Google Scholar]
  • 3. Bedecs K, Langel U, Bartfai T. Metabolism of galanin and galanin (1–16) in isolated cerebrospinal fluid and spinal cord membranes from rat. Neuropeptides 1995;29 (3): 137–143. [DOI] [PubMed] [Google Scholar]
  • 4. Benzing WC, Kordower JH, Mufson EJ. Galanin immunoreactivity within the primate basal forebrain: Evolutionary change between monkeys and apes. J Comp Neurol 1993;336 (1): 31–39. [DOI] [PubMed] [Google Scholar]
  • 5. Bersani M, Johnsen AH, Hojrup P, Dunning BE, Andreasen JJ, Holst JJ. Human galanin: Primary structure and identification of two molecular forms. FEBS Lett 1991;283 (2): 189–194. [DOI] [PubMed] [Google Scholar]
  • 6. Berthold M, Bartfai T. Modes of peptide binding in G protein‐coupled receptors. Neurochem Res 1997;22 (8): 1023–1031. [DOI] [PubMed] [Google Scholar]
  • 7. Bloomquist BT, Beauchamp MR, Zhelnin L, et al. Cloning and expression of the human galanin receptor GALR2. Biochem Biophys Res Commun 1998;243 (2): 474–479. [DOI] [PubMed] [Google Scholar]
  • 8. Borowsky B, Walker MW, Huang LY, et al. Cloning and characterization of the human galanin GALR2 receptor. Peptides 1998;19 (10): 1771–1781. [DOI] [PubMed] [Google Scholar]
  • 9. Bowser R, Kordower JH, Mufson EJ. A confocal microscopic analysis of galaninergic hyperinnervation of cholinergic basal forebrain neurons in Alzheimer's disease. Brain Pathol 1997;7 (2): 723–730. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 10. Branchek TA, Smith KE, Gerald C, Walker MW. Galanin receptor subtypes. Trends Pharmacol Sci 2000;21 (3): 109–117. [DOI] [PubMed] [Google Scholar]
  • 11. Burazin TC, Gundlach AL. Inducible galanin and GALR2 receptor system in motor neuron injury and regeneration. J Neurochem 1998;71 (2): 879–882. [DOI] [PubMed] [Google Scholar]
  • 12. Burazin TC, Larm JA, Ryan MC, Gundlach AL. Galanin‐R1 and ‐R2 receptor mRNA expression during the development of rat brain suggests differential subtype involvement in synaptic transmission and plasticity. Eur J Neurosci 2000;12 (8): 2901–2917. [DOI] [PubMed] [Google Scholar]
  • 13. Burgevin MC, Loquet I, Quarteronet D, Habert‐Ortoli E. Cloning, pharmacological characterization, and anatomical distribution of a rat cDNA encoding for a galanin receptor. J Mol Neurosci 1995;6 (1): 33–41. [DOI] [PubMed] [Google Scholar]
  • 14. Chan‐Palay V. Alterations in the locus coeruleus in dementias of Alzheimer's and Parkinson's disease. Prog Brain Res 1991;88:625–630. [DOI] [PubMed] [Google Scholar]
  • 15. Chan‐Palay V. Galanin hyperinnervates surviving neurons of the human basal nucleus of Meynert in dementias of Alzheimer's and Parkinson's disease: A hypothesis for the role of galanin in accentuating cholinergic dysfunction in dementia. J Comp Neurol 1988;273 (4): 543–557. [DOI] [PubMed] [Google Scholar]
  • 16. Chu M., Mierzwa R., Truummes I, et al. A new fungal metabolite, Sch 202596, with inhibitory activity in the galanin receptor GALR1 assay. Tetrahedon Lett 1997;38:6111–6114. [Google Scholar]
  • 17. Corness JD, Burbach JP, Hokfelt T. The rat galanin‐gene promoter: response to members of the nuclear hormone receptor family, phorbol ester and forskolin. Brain Res Mol Brain Res 1997;47 (1–2): 11–23. [DOI] [PubMed] [Google Scholar]
  • 18. Cortes R, Villar MJ, Verhofstad A, Hokfelt T. Effects of central nervous system lesions on the expression of galanin: A comparative in situ hybridization and immunohistochemical study. Proc Natl Acad Sci USA 1990;87 (19): 7742–7746. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 19. Crawley JN, Austin MC, Fiske SM, et al. Activity of centrally administered galanin fragments on stimulation of feeding behavior and on galanin receptor binding in the rat hypothalamus. J Neurosci 1990;10 (11): 3695–3700. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 20. Crawley JN. Minireview. Galanin‐acetylcholine interactions: relevance to memory and Alzheimer's disease. Life Sci 1996;58 (24): 2185–2199. [DOI] [PubMed] [Google Scholar]
  • 21. Davis KL, Thal LJ, Gamzu ER, et al. A double‐blind, placebo‐controlled multicenter study of tacrine for Alzheimer's disease. The Tacrine Collaborative Study Group. N Engl J Med 1992;327 (18): 1253–1259. [DOI] [PubMed] [Google Scholar]
  • 22. Deecher DC, Mash DC, Staley JK, Mufson EJ. Characterization and localization of galanin receptors in human entorhinal cortex. Regul Pept 1998;73 (3): 149–159. [DOI] [PubMed] [Google Scholar]
  • 23. Deecher DC, Odusan OO, Mufson EJ. Galanin receptors in human basal forebrain differ from receptors in the hypothalamus: Characterization using [125I]galanin (porcine) and [125I]galantide. J Pharmacol Exp Ther 1995;275 (2): 720–727. [PubMed] [Google Scholar]
  • 24. Depczynski B, Nichol K, Fathi Z, Iismaa T, Shine J, Cunningham A. Distribution and characterization of the cell types expressing GALR2 mRNA in brain and pituitary gland. Ann NY Acad Sci 1998;863:120–128. [DOI] [PubMed] [Google Scholar]
  • 25. Diez M, Koistinaho J, Kahn K, Games D, Hokfelt T. Neuropeptides in hippocampus and cortex in transgenic mice overexpressing V717F beta‐amyloid precursor protein — initial observations. Neuroscience 2000;100 (2): 259–286. [DOI] [PubMed] [Google Scholar]
  • 26. Dutar P, Lamour Y, Nicoll RA. Galanin blocks the slow cholinergic EPSP in CA 1 pyramidal neurons from ventral hippocampus. Eur J Pharmacol 1989;164 (2): 355–360. [DOI] [PubMed] [Google Scholar]
  • 27. Evans HF, Shine J. Human galanin: Molecular cloning reveals a unique structure. Endocrinology 1991;129 (3): 1682–1684. [DOI] [PubMed] [Google Scholar]
  • 28. Farlow M, Gracon SI, Hershey LA, Lewis KW, Sadowsky CH, Dolan‐Ureno J. A controlled trial of tacrine in Alzheimer's disease. The Tacrine Study Group. JAMA 1992;268 (18): 2523–2529. [PubMed] [Google Scholar]
  • 29. Fathi Z, Battaglino PM, Iben LG, et al. Molecular characterization, pharmacological properties and chromosomal localization of the human GALR2 galanin receptor. Brain Res Mol Brain Res 1998;58 (1–2): 156–169. [DOI] [PubMed] [Google Scholar]
  • 30. Fathi Z, Cunningham AM, Iben LG, et al. Cloning, pharmacological characterization and distribution of a novel galanin receptor. Brain Res Mol Brain Res 1997;51 (1–2): 49–59. [DOI] [PubMed] [Google Scholar]
  • 31. Faure‐Virelizier C, Croix D, Bouret S, et al. Effects of estrous cyclicity on the expression of the galanin receptor Gal‐R1 in the rat preoptic area: A comparison with the male. Endocrinology 1998;139 (10): 4127–4139. [DOI] [PubMed] [Google Scholar]
  • 32. Fisone G, Berthold M, Bedecs K, et al. N‐terminal galanin‐(1–16) fragment is an agonist at the hippocampal galanin receptor. Proc Natl Acad Sci USA 1989;86 (23): 9588–9591. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 33. Fisone G, Wu CF, Consolo S, et al. Galanin inhibits acetylcholine release in the ventral hippocampus of the rat: Histochemical, autoradiographic, in vivo, and in vitro studies. Proc Natl Acad Sci USA 1987;84 (20): 7339–7343. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 34. Gabriel SM, Bierer LM, Davidson M, Purohit DP, Perl DP, Harotunian V. Galanin‐like immunoreactivity is increased in the postmortem cerebral cortex from patients with Alzheimer's disease. J Neurochem 1994;62 (4): 1516–1523. [DOI] [PubMed] [Google Scholar]
  • 35. Gerlai R. Targeting genes and proteins in the analysis of learning and memory: Caveats and future directions. Rev Neurosci 2000;11 (1): 15–26. [DOI] [PubMed] [Google Scholar]
  • 36. Gibbs RB. Estrogen and nerve growth factor‐related systems in brain: Effects on basal forebrain cholinergic neurons and implications for learning and memory processes and aging. Ann NY Acad Sci 1994;743:165–19 6; discussion 197–199. [DOI] [PubMed] [Google Scholar]
  • 37. Gleason TC, Dreiling JL, Crawley JN. Rat strain differences in response to galanin on the Morris water task. Neuropeptides 1999;33 (4): 265–270. [DOI] [PubMed] [Google Scholar]
  • 38. Gomez‐Isla T, Price JL, Mc Keel DW, Jr. , Morris JC, Growdon JH, Hyman BT. Profound loss of layer II entorhinal cortex neurons occurs in very mild Alzheimer's disease. J Neurosci 1996;16 (14): 4491–4500. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 39. Gregersen S, Lindskog S, Land T, Langel U, Bartfai T, Ahren B. Blockade of galanin‐induced inhibition of insulin secretion from isolated mouse islets by the non‐methionine containing antagonist M35. Eur J Pharmacol 1993;232 (1): 35–39. [DOI] [PubMed] [Google Scholar]
  • 40. Gu ZF, Rossowski WJ, Coy DH, Pradhan TK, Jensen RT. Chimeric galanin analogs that function as antagonists in the CNS are full agonists in gastrointestinal smooth muscle. J Pharmacol Exp Ther 1993;266 (2): 912–918. [PubMed] [Google Scholar]
  • 41. Gustafson EL, Smith KE, Durkin MM, Gerald C, Branchek TA. Distribution of a rat galanin receptor mRNA in rat brain. Neuroreport 1996;7 (4): 953–957. [DOI] [PubMed] [Google Scholar]
  • 42. Habert‐Ortoli E, Amiranoff B, Loquet I, Laburthe M, Mayaux JF. Molecular cloning of a functional human galanin receptor. Proc Natl Acad Sci USA 1994;91 (21): 9780–9783. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 43. Harrison PS, Henderson Z. Quantitative evidence for increase in galanin‐immunoreactive terminals in the hippocampal formation following entorhinal cortex lesions in the adult rat. Neurosci Lett 1999;266 (1): 41–44. [DOI] [PubMed] [Google Scholar]
  • 44. Hokfelt T, Xu ZQ, Shi TJ, Holmberg K, Zhang X. Galanin in ascending systems. Focus on coexistence with 5‐hydroxytryptamine and noradrenaline. Ann NY Acad Sci 1998;863:252–263. [DOI] [PubMed] [Google Scholar]
  • 45. Hosli E, Hosli L. Cellular localization of estrogen receptors on neurones in various regions of cultured rat CNS: Coexistence with cholinergic and galanin receptors. Int J Dev Neurosci 1999;17 (4): 317–330. [DOI] [PubMed] [Google Scholar]
  • 46. Howard AD, Tan C, Shiao LL, et al. Molecular cloning and characterization of a new receptor for galanin. FEBS Lett 1997;405 (3): 285–290. [DOI] [PubMed] [Google Scholar]
  • 47. Howard G, Peng L, Hyde JF. An estrogen receptor binding site within the human galanin gene. Endocrinology 1997;138 (11): 4649–4656. [DOI] [PubMed] [Google Scholar]
  • 48. Iismaa TP, Fathi Z, Hort YJ, et al. Structural organization and chromosomal localization of three human galanin receptor genes. Ann NY Acad Sci 1998;863:56–63. [DOI] [PubMed] [Google Scholar]
  • 49. Ishunina TA, Swaab DF. Increased expression of estrogen receptor alpha and beta in the nucleus basalis of Meynert in Alzheimer's disease. Neurobiol Aging 2001;22 (3): 417–426. [DOI] [PubMed] [Google Scholar]
  • 50. Jacoby AS, Webb GC, Liu ML, et al. Structural organization of the mouse and human GALR1 galanin receptor genes (Galnr and GALNR) and chromosomal localization of the mouse gene. Genomics 1997;45 (3): 496–508. [DOI] [PubMed] [Google Scholar]
  • 51. Kaplan LM, Spindel ER, Isselbacher KJ, Chin WW. Tissue‐specific expression of the rat galanin gene. Proc Natl Acad Sci USA 1988;85 (4): 1065–1069. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 52. Kask K, Berthold M, Kahl U, Nordvall G, Bartfai T. Delineation of the peptide binding site of the human galanin receptor. EMBO J 1996;15 (2): 236–244. [PMC free article] [PubMed] [Google Scholar]
  • 53. Kohler C, Persson A, Melander T, Theodorsson E, Sedvall G, Hokfelt T. Distribution of galanin‐binding sites in the monkey and human telencephalon: Preliminary observations. Exp Brain Res 1989;75 (2): 375–380. [DOI] [PubMed] [Google Scholar]
  • 54. Kolakowski LF, Jr. , O'Neill GP, Howard AD, et al. Molecular characterization and expression of cloned human galanin receptors GALR2 and GALR3. J Neurochem 1998;71 (6): 2239–51. [DOI] [PubMed] [Google Scholar]
  • 55. Kordower JH, Chu Y, Stebbins GT, et al. Loss and atrophy of layer II entorhinal cortex neurons in elderly people with mild cognitive impairment. Ann Neurol 2001;49 (2): 202–213. [PubMed] [Google Scholar]
  • 56. Kordower JH, Le HK, Mufson EJ. Galanin immunoreactivity in the primate central nervous system. J Comp Neurol 1992;319 (4): 479–500. [DOI] [PubMed] [Google Scholar]
  • 57. Kordower JH, Mufson EJ. Galanin‐like immunoreactivity within the primate basal forebrain: differential staining patterns between humans and monkeys. J Comp Neurol 1990;294 (2): 281–292. [DOI] [PubMed] [Google Scholar]
  • 58. Kowall NW, Beal MF. Galanin‐like immunoreactivity is present in human substantia innominata and in senile plaques in Alzheimer's disease. Neurosci Lett 1989;98 (1): 118–123. [DOI] [PubMed] [Google Scholar]
  • 59. Krall WJ, Sramek JJ, Cutler NR. Cholinesterase inhibitors: A therapeutic strategy for Alzheimer disease. Ann Pharmacother 1999;33 (4): 441–450. [DOI] [PubMed] [Google Scholar]
  • 60. Kulinski T, Wennerberg AB, Rigler R, et al. Conformational analysis of galanin using end to end distance distribution observed by Forster resonance energy transfer. Eur Biophys J 1997;26 (2): 145–154. [DOI] [PubMed] [Google Scholar]
  • 61. Land T, Langel U, Bartfai T. Hypothalamic degradation of galanin(1–29) and galanin(1–16): Identification and characterization of the peptidolytic products. Brain Res 1991;558 (2): 245–250. [DOI] [PubMed] [Google Scholar]
  • 62. Land T, Langel U, Low M, Berthold M, Unden A, Bartfai T. Linear and cyclic N‐terminal galanin fragments and analogs as ligands at the hypothalamic galanin receptor. Int J Pept Protein Res 1991;38 (3): 267–272. [DOI] [PubMed] [Google Scholar]
  • 63. Lorimer DD, Matkowskj K, Benya RV. Cloning, chromosomal location, and transcriptional regulation of the human galanin‐1 receptor gene (GALN1R). Biochem Biophys Res Commun 1997;241 (2): 558–564. [DOI] [PubMed] [Google Scholar]
  • 64. McDonald MP, Gleason TC, Robinson JK, Crawley JN. Galanin inhibits performance on rodent memory tasks. Ann NY Acad Sci 1998;863:305–322. [DOI] [PubMed] [Google Scholar]
  • 65. McDonald MP, Willard LB, Wenk GL, Crawley JN. Coadministration of galanin antagonist M40 with a muscarinic M1 agonist improves delayed nonmatching to position choice accuracy in rats with cholinergic lesions. J Neurosci 1998;18 (13): 5078–5085. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 66. Melander T, Staines WA, Hokfelt T, et al. Galanin‐like immunoreactivity in cholinergic neurons of the septum‐basal forebrain complex projecting to the hippocampus of the rat. Brain Res 1985;360 (1–2): 130–138. [DOI] [PubMed] [Google Scholar]
  • 67. Melander T, Staines WA, Rokaeus A. Galanin‐like immunoreactivity in hippocampal afferents in the rat, with special reference to cholinergic and noradrenergic inputs. Neuroscience 1986;19 (1): 223–240. [DOI] [PubMed] [Google Scholar]
  • 68. Mesulam MM, Mufson EJ, Levey AI, Wainer BH. Cholinergic innervation of cortex by the basal forebrain: Cytochemistry and cortical connections of the septal area, diagonal band nuclei, nucleus basalis (substantia innominata), and hypothalamus in the rhesus monkey. J Comp Neurol 1983;214 (2): 170–197. [DOI] [PubMed] [Google Scholar]
  • 69. Miller MA, Kolb PE, Planas B, Raskind MA. Few cholinergic neurons in the rat basal forebrain coexpress galanin messenger RNA. J Comp Neurol 1998;391 (2): 248–258. [PubMed] [Google Scholar]
  • 70. Miller MA, Kolb PE, Raskind MA. GALR 1 galanin receptor mRNA is co‐expressed by galanin neurons but not cholinergic neurons in the rat basal forebrain. Brain Res Mol Brain Res 1997;52 (1): 121–129. [DOI] [PubMed] [Google Scholar]
  • 71. Mufson EJ, Bothwell M, Kordower JH. Loss of nerve growth factor receptor‐containing neurons in Alzheimer's disease: A quantitative analysis across subregions of the basal forebrain. Exp Neurol 1989;105 (3): 221–232. [DOI] [PubMed] [Google Scholar]
  • 72. Mufson EJ, Cochran E, Benzing W, Kordower JH. Galaninergic innervation of the cholinergic vertical limb of the diagonal band (Ch2) and bed nucleus of the stria terminalis in aging, Alzheimer's disease and Down's syndrome. Dementia 1993;4 (5): 237–250. [DOI] [PubMed] [Google Scholar]
  • 73. Mufson EJ, Deecher DC, Basile M, Izenwasse S, Mash DC. Galanin receptor plasticity within the nucleus basalis in early and late Alzheimer's disease: An in vitro autoradiographic analysis. Neuropharmacology 2000;39 (8): 1404–1412. [DOI] [PubMed] [Google Scholar]
  • 74. Mufson EJ, Kahl U, Bowser R, Mash DC, Kordower JH, Deecher DC. Galanin expression within the basal forebrain in Alzheimer's disease. Comments on therapeutic potential. Ann NY Acad Sci 1998;863:291–304. [DOI] [PubMed] [Google Scholar]
  • 75. Mulvaney JM, Parsons RL. Arachidonic acid may mediate the galanin‐induced hyperpolarization in parasympathetic neurons from Necturus maculosus. Neurosci Lett 1995;187 (2): 95–98. [DOI] [PubMed] [Google Scholar]
  • 76. Murphy DD, Cole NB, Greenberger V, Segal M. Estradiol increases dendritic spine density by reducing GABA neurotransmission in hippocampal neurons. J Neurosci 1998;18 (7): 2550–2559. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 77. O'Donnell D, Ahmad S, Wahlestedt C, Walker P. Expression of the novel galanin receptor subtype GALR2 in the adult rat CNS: Distinct distribution from GALR1. J Comp Neurol 1999;409 (3): 469–481. [PubMed] [Google Scholar]
  • 78. Ogren SO, Hokfelt T, Kask K, Langel U, Bartfai T. Evidence for a role of the neuropeptide galanin in spatial learning. Neuroscience 1992;51(1): 1–5. [DOI] [PubMed] [Google Scholar]
  • 79. O'Meara G, Coumis U, Ma SY, et al. Galanin regulates the postnatal survival of a subset of basal forebrain cholinergic neurons. Proc Natl Acad Sci USA 2000;97 (21): 11569–11574. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 80. Ortego J, Coca‐Prados M. Molecular identification and coexpression of galanin and GALR‐1 galanin receptor in the human ocular ciliary epithelium: Differential modulation of their expression by the activation of alpha2‐ and beta2‐adrenergic receptors in cultured ciliary epithelial cells. J Neurochem 1998;71 (6): 2260–2270. [DOI] [PubMed] [Google Scholar]
  • 81. Palazzi E, Felinska S, Zambelli M, Fisone G, Bartfai T, Consolo S. Galanin reduces carbachol stimulation of phosphoinositide turnover in rat ventral hippocampus by lowering Ca2+ influx through voltage‐ sensitive Ca2+ channels. J Neurochem 1991;56 (3): 739–747. [DOI] [PubMed] [Google Scholar]
  • 82. Pang L, Hashemi T, Lee HJ, et al. The mouse GALR2 galanin receptor: Genomic organization, cDNA cloning, and functional characterization. J Neurochem 1998;71 (6): 2252–2259. [DOI] [PubMed] [Google Scholar]
  • 83. Parker EM, Izzarelli DG, Nowak HP, et al. Cloning and characterization of the rat GALR1 galanin receptor from Rin14B insulinoma cells. Brain Res Mol Brain Res 1995;34 (2): 179–189. [DOI] [PubMed] [Google Scholar]
  • 84. Perez SE, Wynick D, Steiner RA, Mufson EJ. Distribution of galaninergic immunoreactivity in the brain of the mouse. J Comp Neurol 2001;434 (2): 158–185. [DOI] [PubMed] [Google Scholar]
  • 85. Pieribone VA, Xu ZQ, Zhang X, Grillner S, Bartfai T, Hokfelt T. Galanin induces a hyperpolarization of norepinephrine‐containing locus coeruleus neurons in the brainstem slice. Neuroscience 1995;64 (4): 861–874. [DOI] [PubMed] [Google Scholar]
  • 86. Planas B, Kolb PE, Raskind MA, Miller MA. Nerve growth factor induces galanin gene expression in the rat basal forebrain: Implications for the treatment of cholinergic dysfunction. J Comp Neurol 1997;379 (4): 563–570. [PubMed] [Google Scholar]
  • 87. Reimann W, Englberger W, Friderichs E, Selve N, Wilffert B. Spinal antinociception by morphine in rats is antagonised by galanin receptor antagonists. Naunyn Schmiedeberg's Arch Pharmacol 1994;350 (4): 380–386. [DOI] [PubMed] [Google Scholar]
  • 88. Rodriguez‐Puertas R, Nilsson S, Pascual J, Pazos A, Hokfelt T. 125I‐galanin binding sites in Alzheimer's disease: Increases in hippocampal subfields and a decrease in the caudate nucleus. J Neurochem 1997;68 (3): 1106–1113. [DOI] [PubMed] [Google Scholar]
  • 89. Rokaeus A, Jiang K, Spyrou G, Waschek JA. Transcriptional control of the galanin gene. Tissue‐specific expression and induction by NGF, protein kinase C, and estrogen. Ann NY Acad Sci 1998;863:1–13. [DOI] [PubMed] [Google Scholar]
  • 90. Rokaeus A, Waschek JA. Primary sequence and functional analysis of the bovine galanin gene promoter in human neuroblastoma cells. DNA Cell Biol 1994;13 (8): 845–855. [DOI] [PubMed] [Google Scholar]
  • 91. Rugarn O, Theodorsson A, Hammar M, Theodorsson E. Effects of estradiol, progesterone, and norethisterone on regional concentrations of galanin in the rat brain. Peptides 1999;20 (6): 743–748. [DOI] [PubMed] [Google Scholar]
  • 92. Sakurai E, Maeda T, Kaneko S, Akaike A, Satoh M. Galanin inhibits long‐term potentiation at Schaffer collateral‐CA1 synapses in guinea‐pig hippocampal slices. Neurosci Lett 1996;212 (1): 21–24. [DOI] [PubMed] [Google Scholar]
  • 93. Samama P, Griffith M, Ohlmeyer M, Webb ML. Non‐peptidergic ligands of the Gal R1 receptor. Neuropeptides 1999;33(4): 311. [Google Scholar]
  • 94. Schneider LS, Farlow MR, Henderson VW, Pogoda JM. Effects of estrogen replacement therapy on response to tacrine in patients with Alzheimer's disease. Neurology 1996;46 (6): 1580–1584. [DOI] [PubMed] [Google Scholar]
  • 95. Scott MK, Ross TM, Lee DH, et al. 2,3‐Dihydro‐dithiin and ‐dithiepine‐1,1,4,4‐tetroxides: Small molecule non‐peptide antagonists of the human galanin hGAL‐1 receptor. Bioorg Med Chem 2000;8 (6): 1383–1391. [DOI] [PubMed] [Google Scholar]
  • 96. Smith KE, Forray C, Walker MW, et al. Expression cloning of a rat hypothalamic galanin receptor coupled to phosphoinositide turnover. J Biol Chem 1997;272 (39): 24612–24616. [DOI] [PubMed] [Google Scholar]
  • 97. Smith KE, Walker MW, Artymyshyn R, et al. Cloned human and rat galanin GALR3 receptors. Pharmacology and activation of G‐protein inwardly rectifying K+ channels. J Biol Chem 1998;273 (36): 23321–23326. [DOI] [PubMed] [Google Scholar]
  • 98. Steiner RA, Hohmann JG, Holmes A, et al. Galanin transgenic mice display cognitive and neurochemical deficits characteristic of Alzheimer's disease. Proc Natl Acad Sci USA 2001;98 (7): 4184–4189. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 99. Takahashi T, Belvisi MG, Barnes PJ. Modulation of neurotransmission in guinea‐pig airways by galanin and the effect of anew antagonist galantide. Neuropeptides 1994;26 (4): 245–251. [DOI] [PubMed] [Google Scholar]
  • 100. Tatemoto K, Rokaeus A, Jornvall H, McDonald TJ, Mutt V. Galanin — a novel biologically active peptide from porcine intestine. FEBS Lett 1983;164 (1): 124–128. [DOI] [PubMed] [Google Scholar]
  • 101. Vrontakis ME, Peden LM, Duckworth ML, Friesen HG. Isolation and characterization of a complementary DNA (galanin) clone from estrogen‐induced pituitary tumor messenger RNA. J Biol Chem 1987;262 (35): 16755–16758. [PubMed] [Google Scholar]
  • 102. Walker LC, Rance NE, Price DL, Young WS, 3rd . Galanin mRNA in the nucleus basalis of Meynert complex of baboons and humans. J Comp Neurol 1991;303 (1): 113–120. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 103. Walli R, Schafer H, Morys‐Wortmann C, Paetzold G, Nustede R, Schmidt WE. Identification and biochemical characterization of the human brain galanin receptor. J Mol Endocrinol 1994;13 (3): 347–356. [DOI] [PubMed] [Google Scholar]
  • 104. Wang S, Hashemi T, Fried S, Clemmons AL, Hawes BE. Differential intracellular signaling of the GALR1 and GALR2 galanin receptor subtypes. Biochemistry 1998;37 (19): 6711–6717. [DOI] [PubMed] [Google Scholar]
  • 105. Wang S, Hashemi T, He C, Strader C, Bayne M. Molecular cloning and pharmacological characterization of a new galanin receptor subtype. Mol Pharmacol 1997;52 (3): 337–343. [DOI] [PubMed] [Google Scholar]
  • 106. Waters SM, Krause JE. Distribution of galanin‐1, ‐2 and ‐3 receptor messenger RNAs in central and peripheral rat tissues. Neuroscience 2000;95 (1): 265–271. [DOI] [PubMed] [Google Scholar]
  • 107. Wennerberg AB, Cooke RM, Carlquist M, Rigler R, Campbell ID. A 1H NMR study of the solution conformation of the neuropeptide galanin. Biochem Biophys Res Commun 1990;166 (3): 1102–1109. [DOI] [PubMed] [Google Scholar]
  • 108. Wiesenfeld‐Hallin Z, Xu XJ, Hao JX, Hokfelt T. The behavioural effects of intrathecal galanin on tests of thermal and mechanical nociception in the rat. Acta Physiol Scand 1993;147 (4): 457–458. [DOI] [PubMed] [Google Scholar]
  • 109. Wilcock GK, Esiri MM, Bowen DM, Smith CC. Alzheimer's disease. Correlation of cortical choline acetyltransferase activity with the severity of dementia and histological abnormalities. J Neurol Sci 1982;57 (2–3): 407–417. [DOI] [PubMed] [Google Scholar]
  • 110. Wittau N, Grosse R, Kalkbrenner F, Gohla A, Schultz G, Gudermann T. The galanin receptor type 2 initiates multiple signaling pathways in small cell lung cancer cells by coupling to G(q), G(i) and G(12) proteins. Oncogene 2000;19 (37): 4199–4209. [DOI] [PubMed] [Google Scholar]
  • 111. Wrenn CC, Crawley JN. Pharmacological evidence supporting a role for galanin in cognition and affect. Prog Neuropsychopharmacol Biol Psychiatry 2001;25 (1): 283–299. [DOI] [PubMed] [Google Scholar]
  • 112. Wynick D, Small CJ, Bloom SR, Pachnis V. Targeted disruption of the murine galanin gene. Ann NY Acad Sci 1998;863:22–47. [DOI] [PubMed] [Google Scholar]
  • 113. Xu H, Gouras GK, Greenfield JP, et al. Estrogen reduces neuronal generation of Alzheimer beta‐amyloid peptides. Nat Med 1998;4 (4): 447–451. [DOI] [PubMed] [Google Scholar]
  • 114. Schreiber S, Getslev V, Weizman A, et al. The antinociceptive effect of moclobemide in mice is mediated by noradrenergic pathways. Neurosci Lett 1998;253:183–186. [DOI] [PubMed] [Google Scholar]
  • 115. Xu ZQ, Shi TJ, Landry M, Hokfelt T. Evidence for galanin receptors in primary sensory neurones and effect of axotomy and inflammation. Neuroreport 1996;8 (1): 237–242. [DOI] [PubMed] [Google Scholar]
  • 116. Xu ZQ, Zhang X, Pieribone VA, Grillner S, Hokfelt T. Galanin — 5‐hydroxytryptamine interactions: Electrophysiological, immunohistochemical and in situ hybridization studies on rat dorsal raphe neurons with a note on galanin R1 and R2 receptors. Neuroscience 1998;87 (1): 79–94. [DOI] [PubMed] [Google Scholar]
  • 117. Zachariou V, Georgescu D, Kansal L, Merriam P, Picciotto MR. Galanin receptor 1 gene expression is regulated by cyclic AMP through a CREB‐dependent mechanism. J Neurochem 2001;76 (1): 191–200. [DOI] [PubMed] [Google Scholar]
  • 118. Zachariou V, Thome J, Parikh K, Picciotto MR. Upregulation of galanin binding sites and GALR1 mRNA levels in the mouse locus coeruleus following chronic morphine treatments and precipitated morphine withdrawal. Neuropsychopharmacology 2000;23 (2): 127–137. [DOI] [PubMed] [Google Scholar]
  • 119. Zhang X, Verge VM, Wiesenfeld‐Hallin Z, Piehl F, Hokfelt T. Expression of neuropeptides and neuropeptide mRNAs in spinal cord after axotomy in the rat, with special reference to motoneurons and galanin. Exp Brain Res 1993;93 (3): 450–461. [DOI] [PubMed] [Google Scholar]

Articles from CNS Drug Reviews are provided here courtesy of Wiley

RESOURCES